{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:38:49Z","timestamp":1793813929011,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103630","type":"journal-article","created":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T15:49:48Z","timestamp":1721144988000},"page":"103630","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity"],"prefix":"10.1016","volume":"9","author":[{"given":"I.-A.","family":"Mavroeidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Burghofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kalbourtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0927-6498","authenticated-orcid":false,"given":"H.","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5654-6190","authenticated-orcid":false,"given":"G.","family":"Webersinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Piringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Liffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reichinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2806-4594","authenticated-orcid":false,"given":"P.","family":"Kirchweger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.A.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2166-3394","authenticated-orcid":false,"given":"M.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.W.","family":"Prager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-1830","authenticated-orcid":false,"given":"D.","family":"Kersting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Treckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-7050","authenticated-orcid":false,"given":"H.-U.","family":"Schildhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rumpold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4778","authenticated-orcid":false,"given":"J.T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4813-4435","authenticated-orcid":false,"given":"B.","family":"Doleschal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.103630_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"Blechacz","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.esmoop.2024.103630_bib2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","article-title":"Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial","volume":"87","author":"Verlingue","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103630_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-42083-4","article-title":"Real world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment","volume":"13","author":"Doleschal","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103630_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103630_bib5","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO Scale for Clinical Actionability of molecular Targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103630_bib6","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A\u00a0framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103630_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103630_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination\u2013related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103630_bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2024.103630_bib10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ejca.2022.10.021","article-title":"Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: a current perspective","volume":"179","author":"Herzog","year":"2023","journal-title":"Eur J Cancer"},{"issue":"D1","key":"10.1016\/j.esmoop.2024.103630_bib11","doi-asserted-by":"crossref","first-page":"D835","DOI":"10.1093\/nar\/gkz972","article-title":"ClinVar: improvements to accessing data","volume":"48","author":"Landrum","year":"2019","journal-title":"Nucleic acids Res"},{"issue":"D1","key":"10.1016\/j.esmoop.2024.103630_bib12","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","article-title":"COSMIC: a curated database of somatic variants and clinical data for cancer","volume":"52","author":"Sondka","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103630_bib13","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","article-title":"VarSome: the human genomic variant search engine","volume":"35","author":"Kopanos","year":"2019","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103630_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"24","key":"10.1016\/j.esmoop.2024.103630_bib16","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1200\/JCO.2007.12.1368","article-title":"End points in advanced colon cancer clinical trials: a review and proposal","volume":"25","author":"Allegra","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103630_bib17","first-page":"1","article-title":"Determining the late effect parameter in the Fleming-Harrington test using asymptotic relative efficiency in cancer immunotherapy clinical trials","author":"Kaneko","year":"2023","journal-title":"J\u00a0Biopharm Stat"},{"issue":"15","key":"10.1016\/j.esmoop.2024.103630_bib18","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1158\/1078-0432.CCR-19-0127","article-title":"Alterations in DNA damage repair genes in primary liver cancer","volume":"25","author":"Lin","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103630_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000682","article-title":"Molecular profile of BRCA-mutated biliary tract cancers","volume":"5","author":"Spizzo","year":"2020","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103630_bib20","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"issue":"7766","key":"10.1016\/j.esmoop.2024.103630_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41586-019-1382-1","article-title":"Tumour lineage shapes BRCA-mediated phenotypes","volume":"571","author":"Jonsson","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103630_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/1078-0432.CCR-22-2551","article-title":"Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation","volume":"29","author":"Serra-Camprub\u00ed","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103630_bib23","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-21-2096","article-title":"Pan-cancer analysis of homologous recombination repair\u2013associated gene alterations and genome-wide loss-of-heterozygosity ScorePan-cancer gLOH and HRR-associated gene alterations","volume":"28","author":"Westphalen","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103630_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.10.104","article-title":"68O Impact of mutation status on efficacy outcomes in TOPAZ-1: a phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)","volume":"33","author":"Valle","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103630_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejca.2019.07.022","article-title":"Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker","volume":"120","author":"Chae","year":"2019","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103630_bib26","first-page":"2854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.esmoop.2024.103630_bib27","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ejca.2022.05.004","article-title":"Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma","volume":"171","author":"Rimini","year":"2022","journal-title":"Eur J Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103630_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.2023.41.4_suppl.593","volume":"41","author":"Lamarca","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2024.103630_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103630_bib30","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103630_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41416-018-0138-2","article-title":"A\u00a0randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin","volume":"119","author":"Zheng","year":"2018","journal-title":"Br J cancer"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103630_bib32","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/cancers15113047","article-title":"Third-line palliative systemic therapy for advanced biliary tract cancer: multicentre review of patterns of care and outcomes","volume":"15","author":"Gray","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.esmoop.2024.103630_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00567","article-title":"Repeat next-generation sequencing testing on progression in men with metastatic prostate cancer can identify new actionable alterations","volume":"8","author":"Park","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103630_bib34","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1200\/JCO.2023.41.16_suppl.4087","article-title":"Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer","volume":"41","author":"O\u2019Bryan","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103630_bib35","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103630_bib36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41698-023-00409-5","article-title":"PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system","volume":"7","author":"Zimmer","year":"2023","journal-title":"NPJ Precis Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:06:37Z","timestamp":1737331597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924013991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924013991"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103630","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103630","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103630"}}